The equine antimicrobial peptide eCATH1 is effective against the facultative intracellular pathogen rhodococcus equi in mice

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 4615-4621

  Schlusselhuber, Margot ^a   Torelli, Riccardo ^b   Martini, Cecilia ^b   Leippe, Matthias ^c   Cattoir, Vincent ^d,e   Leclercq, Roland ^d,e   Laugier, Claire ^a   Grötzinger, Joachim ^c   Sanguinetti, Maurizio ^b   Cauchard, Julien ^a  

^a FRENCH AGENCY FOR FOOD   (France)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF KIEL   (Germany)

^d CAEN UNIVERSITY HOSPITAL   (France)

^e UNIVERSITÉ DE CAEN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ECATH1 PEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; RIFAMPICIN; UNCLASSIFIED DRUG;

ACTINOMYCETALES INFECTION; ALPHA HELIX; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL COUNT; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERICIDAL ACTIVITY; CELL PERMEABILIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EX VIVO STUDY; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RHODOCOCCOSIS; RHODOCOCCUS EQUI; TREATMENT DURATION;

ACTINOMYCETALES INFECTIONS; ANIMALS; ANTI-INFECTIVE AGENTS; CELL LINE; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MICROSCOPY, FLUORESCENCE; RHODOCOCCUS EQUI; RIFAMPIN;

EID: 84884221598     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02044-12     Document Type: Article

References (36)

1. Magnusson H. 1923. Spezifische infektiose pneumonie biem fohlen. Ein neurer eiterreger biem pferd. Arch. Wiss. Prakt. Tierheilk. 50:22-38.
2. Mauger C. 2009. Retrospective study of equine rhodococcosis observed at autopsy on 1617 foals at the "LERPE" (AFSSA, Dozulé) from 1986 to 2006. D.V.M. thesis. Université Paul-Sabatier de Toulouse, Toulouse, France. (In French.)
3. Laugier C. 2004. Rhodococcose: bilan partiel des cas enregistrés à l'autopsie en 2004 (du 1er janvier au 26 août). Bull. Réseau Epidémiosurveill. Pathol. Equine 13:3.
4. Takai S, Sasaki Y, Tsubaki S. 1995. Rhodococcus equi infection in foals: current concepts and implication for future research. J. Equine Sci. 6:105- 119.
5. Yager JA. 1987. The pathogenesis of Rhodococcus equi pneumonia in foals. Vet. Microbiol. 14:225-232.
6. Weinstock DM, Brown AE. 2002. Rhodococcus equi: an emerging pathogen. Clin. Infect. Dis. 34:1379-1385.
7. Golub B, Falk G, Spink W. 1967. Lung abscess due to Corynebacterium equi. Report of first human infection. Ann. Intern. Med. 66:1174-1177.
8. Topino S, Galati V, Grilli E, Petrosillo N. 2010. Rhodococcus equi infection in HIV-infected individuals: case reports and review of the literature. AIDS Patient Care STDS 24:211-222.
9. Yamshchikov AV, Schuetz A, Lyon GM. 2010. Rhodococcus equi infection. Lancet Infect. Dis. 10:350-359.
10. Heidmann P, Madigan JE, watson, JL. 2006. Rhodococcus equi pneumonia: clinical findings, diagnosis, treatment and prevention. Clin. Tech. Equine Pract. 5:203-2010.
11. Asoh N, Watanabe H, Fines-Guyon M, Watanabe K, Oishi K, Kositsakulchai W, Sanchai T, Kunsuikmengrai K, Kahintapong S, Khantawa B, Tharavichitkul P, Sirisanthana T, Nagatake T. 2003. Emergence of rifampin-resistant Rhodococcus equi with several types of mutations in the rpoB gene among AIDS patients in northern Thailand. J. Clin. Microbiol. 41:2337-2340.
12. Boyen F, Pasmans F, Haesebrouck F. 2011. Acquired antimicrobial resistance in equine Rhodococcus equi isolates. Vet. Rec. 168:101.
13. Buckley TM, Stanbridge ES. 2007. Resistance studies of erythromycine and rifampin for Rhodococcus equi over a 10-year period. Irish Vet. J. 60:728-731.
14. Kenney DG, Robbins SC, Prescott JF, Kaushik A, Baird JD. 1994. Development of reactive arthritis and resistance to erythromycin and rifampin in a foal during treatment for Rhodococcus equi pneumonia. Equine Vet. J. 26:246-248.
15. Hancock RE, Sahl HG. 2006. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24:1551-1557.
16. Levy SB, Marshall B. 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10:S122-S129.
17. Zucca M, Savoia D. 2010. The post-antibiotic era: promising developments in the therapy of infectious diseases. Int. J. Biomed. Sci. 6:77-85.
18. Steinstraesser L, Kraneburg UM, Hirsch T, Kesting M, Steinau HU, Jacobsen F, Al-Benna S. 2009. Host defense peptides as effector molecules of the innate immune response: a sledgehammer for drug resistance? Int. J. Mol. Sci. 10:3951-3970.
19. Schlusselhuber M, Jung S, Bruhn O, Goux D, Leippe M, Leclercq R, Laugier C, Grötzinger J, Cauchard J. 2012. In vitro potential of equine DEFA1 and eCATH1 as alternative antimicrobial drugs in rhodococcosis treatment. Antimicrob. Agents Chemother. 56:1749-1755.
20. Thulin P, Johansson L, Low DE, Gan BS, Kotb M, McGeer A, Norrby- Teglund A. 2006. Viable group A streptococci in macrophages during acute soft tissue infection. PLoS Med. 3:e53. doi:10.1371/journal.pmed .0030053.
21. Verneuil N, Sanguinetti M, Le Breton Y, Posteraro B, Fadda G, Auffray Y, Hartke A, Giard JC. 2004. Effects of the Enterococcus faecalis hypR gene encoding a new transcriptional regulator on oxidative stress response and intracellular survival within macrophages. Infect. Immun. 72:4424-4431.
22. Gentry-Weeks CR, Karkhoff-Schweizer R, Pikis A, Estay M, Keith JM. 1999. Survival of Enterococcus faecalis in mouse peritoneal macrophages. Infect. Immun. 67:2160-2165.
23. Takai S, Sasaki Y, Tsubaki S. 1992. Influence of inoculation route on virulence of Rhodococcus equi in mice. Microbiol. Immunol. 36:895-898.
24. Nordmann P, Kerestedjian JJ, Ronco E. 1992. Therapy of Rhodococcus equi disseminated infections in nude mice. Antimicrob. Agents Chemother. 36:1244-1248.
25. Cirioni O, Silvestri C, Ghiselli R, Orlando F, Riva A, Mocchegiani F, Chiodi L, Castelletti S, Gabrielli E, Saba V, Scalise G, Giacometti A. 2008. Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection. J. Antimicrob. Chemother. 62:1332-1338.
26. Sharma S, Verma I, Khuller GK. 2001. Therapeutic potential of human neutrophil peptide 1 against experimental tuberculosis. Antimicrob. Agents Chemother. 45:639-640.
27. Sharma S, Verma I, Khuller GK. 2000. Antibacterial activity of human neutrophil peptide-1 against Mycobacterium tuberculosis H37Rv: in vitro and ex vivo study. Eur. Respir. J. 16:112-117.
28. Jena P, Mishra B, Leippe M, Hasilik A, Griffiths G, Sonawane A. 2011. Membrane-active antimicrobial peptides and human placental lysosomal extracts are highly active against mycobacteria. Peptides 32:881-887.
29. Yang BD, Chen Q, Schmidt AP, Anderson GM, Wang JM, Wooters J, Oppenheim JJ, Chertov O. 2000. LL-37, the neutrophil granule-and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192:1069-1074.
30. Niyonsaba F, Iwabuchi K, Someya A, Hirata M, Matsuda H, Ogawa H, Nagaoka I. 2002. A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 106:20-26.
31. Bowdish DM, Davidson DJ, Speert DP, Hancock RE. 2004. The human cationic peptide LL-37 induces activation of the extracellular signalregulated kinase and p38 kinase pathways in primary human monocytes. J. Immunol. 172:3758-3765.
32. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE. 2005. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 77: 451-459.
33. Mookherjee N, Brown KL, Bowdish DM, Doria S, Falsafi R, Hokamp K, Roche FM, Mu R, Doho GH, Pistolic J, Powers JP, Bryan J, Brinkman FS, Hancock RE. 2006. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol. 176:2455-2464.
34. Tan BH, Meinken C, Bastian M, Bruns H, Legaspi A, Ochoa MT, Krutzik SR, Bloom BR, Ganz T, Modlin RL, Stenger S. 2006. Macrophages acquire neutrophil granules for antimicrobial activity against intracellular pathogens. J. Immunol. 177:1864-1871.
35. Martens RJ, Cohen ND, Jones SL, Moore TA, Edwards JF. 2005. Protective role of neutrophils in mice experimentally infected with Rhodococcus equi. Infect. Immun. 73:7040-7042.
36. Cassone M, Otvos L, Jr. 2010. Synergy among antibacterial peptides and between peptides and small-molecule antibiotics. Expert Rev. Anti Infect. Ther. 8:703-716.